Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05781321 · ClinicalTrials.gov registry record · Phase 2
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
A Phase 2 study of Glioblastoma, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 8
- Study locations
NCT05781321: Active Phase 2 study of Glioblastoma, sponsored by Mayo Clinic.
NCT05781321 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 170 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (57% higher). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05781321, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 8
- Study locations
Study Summary
This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects.
Primary Outcome
OS is defined as the time from study registration to death due to any cause.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- DRUG Fluorodopa F 18
- RADIATION Accelerated Hypofractionated Radiation Therapy
Study Locations (8)
Minnesota
- Mayo Clinic Health System in Albert Lea - Albert Lea
- Mayo Clinic Health Systems-Mankato - Mankato
- Mayo Clinic Radiation Therapy - Northfield - Northfield
- Mayo Clinic in Rochester - Rochester
Wisconsin
- Mayo Clinic Health System-Eau Claire - Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare - La Crosse
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2028-07-02 |
| Phase | Phase 2 |
What the registry record for NCT05781321 still lists
NCT05781321 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05781321 lists 8 locations in 4 states (Minnesota, Wisconsin, Arizona).
Frequently Asked Questions
What is clinical trial NCT05781321 about?
NCT05781321 is a clinical study titled "Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study". This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with...
What is the current status of trial NCT05781321?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2023-03-23. Estimated completion is 2028-07-02.
What conditions does trial NCT05781321 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05781321?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fluorodopa F 18 (DRUG), Accelerated Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05781321?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05781321 being conducted?
This trial has 8 study locations across Arizona, Florida, Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05781321's enrollment target sits among peer trials
170 29th of 199 higher than 171 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI